
Bernhard Ellinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/336554/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Palmitoylation Machinery Is a Spatially Organizing System for Peripheral Membrane Proteins. Cell, 2010, 141, 458-471.	28.9	393
2	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 2021, 372, 642-646.	12.6	240
3	Multi-endpoint toxicological assessment of polystyrene nano- and microparticles in different biological models in vitro. Toxicology in Vitro, 2019, 61, 104610.	2.4	172
4	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacology and Translational Science, 2021, 4, 1096-1110.	4.9	101
5	Synthesis and Structureâ	13.7	97
6	Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wnt-pathway. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6805-6810.	7.1	91
7	Antiplasmodial Thiostrepton Derivatives: Proteasome Inhibitors with a Dual Mode of Action. Angewandte Chemie - International Edition, 2010, 49, 3317-3321.	13.8	75
8	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Scientific Data, 2021, 8, 70.	5.3	65
9	Selective Chemical Imaging of Static Actin in Live Cells. Journal of the American Chemical Society, 2012, 134, 8480-8486.	13.7	62
10	Generation of Live-Cell Microarrays by Means of DNA-Directed Immobilization of Specific Cell-Surface Ligands. Angewandte Chemie - International Edition, 2007, 46, 4180-4183.	13.8	53
11	A Fluorescent Probe for the 70 Sâ€Ribosomal GTPaseâ€Associated Center. ChemBioChem, 2009, 10, 242-24	52.6	45
12	ATP competitive inhibitors of d-alanine–d-alanine ligase based on protein kinase inhibitor scaffolds. Bioorganic and Medicinal Chemistry, 2009, 17, 1079-1087.	3.0	45
13	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. Journal of Medicinal Chemistry, 2016, 59, 7598-7616.	6.4	41
14	A Bioluminogenic HDAC Activity Assay: Validation and Screening. Journal of Biomolecular Screening, 2011, 16, 1227-1235.	2.6	37
15	A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses. AIDS Research and Therapy, 2013, 10, 1.	1.7	29
16	Establishing the Secondary Metabolite Profile of the Marine Fungus: Tolypocladium geodes sp. MF458 and Subsequent Optimisation of Bioactive Secondary Metabolite Production. Marine Drugs, 2017, 15, 84.	4.6	27
17	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. European Journal of Medicinal Chemistry, 2018, 146, 423-434.	5.5	27
18	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega, 2017, 2, 5666-5683.	3.5	24

Bernhard Ellinger

#	Article	IF	CITATIONS
19	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (Tb GAPDH) and Trypanosoma cruzi trypanothione reductase (Tc TR) and display trypanocidal activity. European Journal of Medicinal Chemistry, 2017, 141, 138-148.	5.5	23
20	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. Journal of Medicinal Chemistry, 2019, 62, 3989-4012.	6.4	21
21	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. European Journal of Medicinal Chemistry, 2017, 126, 1129-1135.	5.5	20
22	Comparison of In-Vitro and Ex-Vivo Wound Healing Assays for the Investigation of Diabetic Wound Healing and Demonstration of a Beneficial Effect of a Triterpene Extract. PLoS ONE, 2017, 12, e0169028.	2.5	19
23	Development of a Colorimetric and a Fluorescence Phosphatase-Inhibitor Assay Suitable for Drug Discovery Approaches. Journal of Biomolecular Screening, 2013, 18, 899-909.	2.6	18
24	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. European Journal of Medicinal Chemistry, 2019, 183, 111676.	5.5	18
25	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discovery, 2019, 24, 346-361.	2.7	18
26	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. Scientific Data, 2022, 9, .	5.3	17
27	Aspergillus sydowii: Genome Analysis and Characterization of Two Heterologous Expressed, Non-redundant Xylanases. Frontiers in Microbiology, 2020, 11, 2154.	3.5	15
28	lterative Antimicrobial Candidate Selection from Informed <scp>D</scp> â€/ <scp>L</scp> â€Peptide Dimer Libraries. ChemBioChem, 2013, 14, 2492-2499.	2.6	14
29	A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism. Patterns, 2022, 3, 100433.	5.9	13
30	Synthesis and Biological Activity of Octaketides from the Cytosporone Family. Israel Journal of Chemistry, 2017, 57, 975-981.	2.3	12
31	Development of a Focused Library of Triazoleâ€Linked Privilegedâ€Structureâ€Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. ChemMedChem, 2018, 13, 678-683.	3.2	12
32	EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. SLAS Discovery, 2019, 24, 398-413.	2.7	12
33	A unique fungal strain collection from Vietnam characterized for high performance degraders of bioecological important biopolymers and lipids. PLoS ONE, 2018, 13, e0202695.	2.5	10
34	A Phenotypic Screening Approach to Identify Anticancer Compounds Derived from Marine Fungi. Assay and Drug Development Technologies, 2014, 12, 162-175.	1.2	9
35	Insights into the genome and secretome of Fusarium metavorans DSM105788 by cultivation on agro-residual biomass and synthetic nutrient sources. Biotechnology for Biofuels, 2021, 14, 74.	6.2	9
36	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. European Journal of Medicinal Chemistry, 2020, 189, 112047.	5.5	8

Bernhard Ellinger

#	Article	IF	CITATIONS
37	Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1. Journal of Medicinal Chemistry, 2022, 65, 9011-9033.	6.4	8
38	Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 333-336.	5.0	5
39	SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- <i>Trypanosoma brucei</i> Agent. ACS Medicinal Chemistry Letters, 2019, 10, 528-533.	2.8	5
40	High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Biomedicine and Pharmacotherapy, 2022, 151, 113104.	5.6	4
41	Design, Synthesis and Antiparasitic Evaluation of Click Phospholipids. Molecules, 2021, 26, 4204.	3.8	3
42	Design, Synthesis and Structure—Activity Relationships of a Phenotypic Small Library against Protozoan Infections. Proceedings (mdpi), 2017, 1, 648.	0.2	2
43	A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1. Viruses, 2020, 12, 580.	3.3	2
44	Genome and Secretome Analysis of Staphylotrichum longicolleum DSM105789 Cultured on Agro-Residual and Chitinous Biomass. Microorganisms, 2021, 9, 1581.	3.6	2
45	The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines. European Journal of Medicinal Chemistry, 2021, 209, 112871.	5.5	1